Friday January 10, 2014
MARSEILLE, France, January 10, 2013 - QIAGEN Marseille (Paris: ALIPS) today announced its intent to focus on innovative biomarkers development and Next Generation Sequencing IVD applications.
This decision will allow QIAGEN Marseille to further focus its resources and accelerate the development and commercialization of its strategic oncology and personalized healthcare programs, in particular Next Generation Sequencing (NGS) for cancer diagnostics, a market segments having a significant growth and business potential.
See press release
distributed by
|